Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gozde K Yardimci"'
Autor:
Melda Bahap-Kara, Emine Sariyildiz, Gozde K. Yardimci, Omer Karadag, Aygin Bayraktar-Ekincioglu
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 4, Pp 1043-1055 (2024)
Abstract Introduction Glucocorticoids (GCs) play a crucial role in the treatment of many rheumatic diseases regarding their anti-inflammatory and immunosuppressive effects. Inappropriate use of GCs can exacerbate GC-related problems besides complex t
Externí odkaz:
https://doaj.org/article/6d83fcfdcba54a9c8af4b3f06f62fce5
Autor:
David Turgeon, Volodko Bakowsky, Corisande Baldwin, David A Cabral, Marie Clements-Baker, Alison Clifford, Jan Willem Cohen Tervaert, Natasha Dehghan, Daniel Ennis, Leilani Famorca, Aurore Fifi-Mah, Louis-Philippe Girard, Frédéric Lefebvre, Patrick Liang, Jean-Paul Makhzoum, David Massicotte-Azarniouch, Arielle Mendel, Nataliya Milman, Heather N Reich, David B Robinson, Carolyn Ross, Dax G Rumsey, Medha Soowamber, Tanveer E Towheed, Judith Trudeau, Marinka Twilt, Elaine Yacyshyn, Gozde K Yardimci, Nader Khalidi, Lillian Barra, Christian Pagnoux
Publikováno v:
Rheumatology.
ObjectiveIn 2020, the Canadian Vasculitis Research Network (CanVasc) published their updated recommendations for the management of ANCA-associated vasculitides (AAV). The current addendum provides further recommendations regarding the use of avacopan
Autor:
Pedro M Machado, Saskia Lawson-Tovey, Anja Strangfeld, Elsa Mateus, Kimme Hyrich, Laure Gossec, Loreto Carmona, Ana Rodrigues, Bernd Raffeiner, Cátia Duarte, Eric Hachulla, Eric Veillard, Eva Strakova, Gerd R Burmester, Gozde K Yardimci, José A Gómez-Puerta, Julija Zepa, Lianne Kearsley-Fleet, Ludovic Trefond, Maria M Cunha, Marta Mosca, Martina Cornalba, Martin Soubrier, Nicolas Roux, Olivier Brocq, Patrick Durez, Richard Conway, Tiphaine Goulenok, Johannes W. J Bijlsma, Iain McInnes, Xavier Mariette
Publikováno v:
Rheumatology. 61
Background/Aims People with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs) were excluded from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine clinical development programmes; therefore, concerns regarding